Thursday, April 27, 2023, San Antonio, Texas, 6:00 PM – 7:30 PM Central Time (7:00 PM – 8:30 PM Eastern Time)

What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation

Fifteenth Annual RTP Symposium Series Held During the Annual ONS Congress

Management of HER2-Expressing Cancers Across the Oncology Spectrum: The Role of Antibody-Drug Conjugates

 
Location
Grand Hyatt San Antonio River Walk
600 E Market Street
San Antonio, TX 78205
Hotel Phone: (210) 224-1234

Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration
6:00 PM – 7:30 PM — Dinner Meeting

Meeting Room
Texas Ballroom (Salons A-C) – Fourth Floor


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Lyudmila A Bazhenova, MD
Professor of Medicine
Lung Cancer Unit Leader
Director, Hematology and Oncology Fellowship Training Program
UC San Diego Moores Cancer Center
San Diego, California

Kelly EH Goodwin, MSN, RN, ANP-BC
Thoracic Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
AB Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas


Caroline Kuhlman, MSN, APRN-BC
Nurse Practitioner
Tucker Gosnell Center for Gastrointestinal Cancers
Massachusetts General Hospital
Boston, Massachusetts

Alexis N McKinney, MSN, AGNP-BC
Adult-Gerontology Nurse Practitioner
Mays Cancer Center
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

Zev Wainberg, MD, MSc
Co-Director, GI Oncology Program
Director of Early Phase Clinical Research
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc during the Oncology Nursing Society’s (ONS) 48th Annual Congress, April 26–30, 2023 in San Antonio, Texas. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration
6:00 PM – 7:30 PM — Educational Dinner Meeting

What I Tell My Patients About ...

The Rationale for Targeting HER2 with Antibody-Drug Conjugates (ADCs) in Cancer Management

  • Spectrum, frequency and prognostic implications of HER2 alterations, such as overexpression/amplification and mutations, in advanced solid tumors
  • Synergistic effect of HER2 inhibition and cytotoxic therapy and scientific explanation for the activity of HER2-targeted ADCs against HER2-positive tumors

The Role of HER2-Targeted ADCs in Therapy for HER2-Positive Breast Cancer

  • Long-term findings with T-DM1 for HER2-positive breast cancer
  • Published research evaluating trastuzumab deruxtecan (T-DXd) for multiregimen-relapsed HER2-positive metastatic breast cancer (mBC)
  • Comparative efficacy observed with T-DXd and T-DM1 among patients with HER2-positive mBC previously treated with trastuzumab and a taxane; implications for therapeutic sequencing
  • Ongoing studies attempting to further define the role of HER2-targeted ADCs in therapy for HER2-positive localized and metastatic breast cancer

New Treatment Options for HER2-Low mBC

  • Incidence and clinical characteristics of HER2-low breast cancer
  • Biologic explanation for the antitumor activity of T-DXd for HER2-low disease
  • Published research supporting the recent FDA approval of T-DXd for patients with previously treated HER2-low advanced breast cancer
  • Optimal sequencing of T-DXd for patients with hormone receptor (HR)-positive and HR-negative, HER2-low mBC

The Use of T-DXd for HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Cancer

  • Published efficacy and safety data with T-DXd in Asian and Western patients with progressive HER2-positive gastric/GEJ cancer
  • FDA approval of T-DXd for metastatic gastric/GEJ adenocarcinoma; optimal sequencing of T-DXd for patients with progressive HER2-positive disease
  • Ongoing clinical trials attempting to further define the role of T-DXd in therapy for gastric/GEJ cancer

The Potential Role of HER2-Targeted ADCs in the Treatment of Metastatic Colorectal Cancer (mCRC)

  • Objective response rate and other clinically relevant endpoints achieved with T-DXd for patients with pretreated HER2-expressing mCRC
  • Ongoing investigation of 2 different doses of T-DXd for HER2-overexpressing mCRC
  • Recent NCCN guideline inclusion of T-DXd for HER2-positive mCRC; current nonresearch role

HER2-Targeted Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

  • Published research supporting the recent FDA approval of T-DXd for NSCLC with HER2 mutations
  • Evidence-based sequencing of T-DXd for patients with NSCLC and HER2 mutations
  • Efficacy outcomes with and potential clinical role for T-DXd for HER2-overexpressing NSCLC

The Incidence and Management of Interstitial Lung Disease (ILD) and Other Toxicities with T-DXd

  • Rates, severity and timing of ILD with T-DXd in clinical trials for various tumor types
  • Appropriate workup for patients with suspected therapy-related ILD; strategies to distinguish drug-related pulmonary issues from other potential causes
  • Guidelines for treatment modification and discontinuation for patients experiencing complications from ILD; indications for restarting T-DXd
  • Utility of other supportive care measures, such as corticosteroids or oxygen supplementation, for patients experiencing ILD
  • Incidence and severity of cytopenias with T-DXd; appropriate monitoring of complete blood counts during therapy
  • Frequency of gastrointestinal side effects, such as diarrhea, nausea and vomiting, with T-DXd

The Potential Role of HER2-Targeted ADCs in Other Tumor Types

  • Efficacy and safety observed with T-DXd in patients with HER2-positive and HER2-low advanced biliary tract cancers
  • Early activity and safety data with HER2-targeted ADCs for HER2-expressing metastatic urothelial bladder cancer
  • Emerging clinical trial findings showing clinically meaningful and durable responses with T-DXd across multiple HER2-expressing tumor types

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate the spectrum and prevalence of HER2 alterations across various solid tumors and the means by which these contribute to tumor growth and proliferation.
  • Consider the scientific justification for the use of antibody-drug conjugates (ADCs) as a therapeutic approach for patients with HER2-altered solid tumors, and recall the mechanisms of antitumor activity of commercially available and investigational HER2-targeted agents.
  • Appraise available clinical research data with novel HER2-directed ADCs for patients with HER2-altered solid tumors, and consider the current and potential role of this approach in routine clinical care.
  • Recognize common and rare side effects associated with HER2-targeted ADCs employed in the care of patients with cancer, and use this information to develop supportive management plans.
  • Recollect ongoing clinical research attempting to further define the role of novel HER2-directed ADCs in treating various tumor types, and counsel appropriate patients regarding the potential benefits of trial participation.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. https://www.researchtopractice.com/Meetings/ONS2023/PanTumorHER2/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Goodwin and Ms McKinney have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Bazhenova — Consulting Agreements: AbbVie Inc, AnHeart Therapeutics, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Elevation Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, InterVenn Biosciences, Janssen Biotech Inc, Merck, Mirati Therapeutics Inc, NEUVOGEN Inc, Novocure Inc, Regeneron Pharmaceuticals Inc, Sanofi, Turning Point Therapeutics Inc; Data and Safety Monitoring Board/Committee: ORIC Pharmaceuticals (completed). Dr Kaklamani — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Puma Biotechnology Inc, TerSera Therapeutics LLC; Contracted Research: Eisai Inc; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Novartis, Pfizer Inc, Seagen Inc. Ms Kuhlman — Nonrelevant Financial Relationship: Clinical Care Options. Dr Wainberg — Advisory Committee and Consulting Agreements: Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Arcus Biosciences, Bristol-Myers Squibb Company, Plexxikon Inc; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc, Pfizer Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.

Grand Hyatt San Antonio River Walk
600 E Market Street
San Antonio, TX 78205
Hotel Phone: (210) 224-1234

Meeting Room:
Texas Ballroom (Salons A-C) – Fourth Floor

The Grand Hyatt San Antonio is the headquarters hotel for the 2023 ONS Congress and is conveniently connected to the Henry B González Convention Center.

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer using HER2-targeted antibody-drug conjugates.

​ ​ ​
IN-PERSON registration
Thank you for your interest in our NCPD program taking place in San Antonio, Texas. At this time online preregistration for in-person is closed for this event. LIMITED SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 5:30 PM Central Time on Thursday, April 27th. If you are interested in attending, please visit our registration desk located outside the Texas Ballroom (Salons A-C) – Fourth Floor of the Grand Hyatt San Antonio River Walk hotel which is connected to the Henry B Gonzalez Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com.

Please note, onsite registration does not guarantee seating and participation in meal service and will be based on availability.

LIVE WEBCAST registration open to all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.